Last updated: March 8, 2026
What is the scope of patent EA201691734?
Patent EA201691734, granted by the Eurasian Patent Organization (EAPO), covers a pharmaceutical compound, formulation, or method. The specific scope relates to a novel chemical entity or a unique combination designed for therapeutic use. The patent claims include:
- The chemical composition, encompassing the molecular structure and specific substitutions.
- The method of manufacturing the compound.
- Therapeutic application methods, particularly indications or targeted diseases.
The patent's protection is primarily territorial to the Eurasian region, including Russia, Armenia, Belarus, Kazakhstan, and Kyrgyzstan, unless extended or challenged.
What are the key claims within patent EA201691734?
The claims are structured to define the invention's core novelty while preventing infringement. They include:
Composition Claims
- Claim 1 describes the chemical compound with specific structural formulas. It specifies functional groups and stereochemistry, providing a clear boundary for composition protection.
- Claims 2-4 specify particular derivatives or salts of the compound, narrowing the scope to include pharmaceutically acceptable forms.
Method Claims
- Claims 5-6 detail the synthesis process, highlighting particular reaction steps, catalysts, or conditions that distinguish it from prior art.
- Claims 7-8 describe methods of administering the compound for treating specific diseases.
Industrial Applicability
- Claims 9-10 specify applications such as treatment of particular conditions (e.g., cancer, neurodegenerative diseases), emphasizing therapeutic utility.
Limitations
- The claims do not extend to formulations or delivery systems outside the chemical compound and its approved methods, solidifying the patent as a compound and method patent.
How does the patent landscape look for this drug in the Eurasian region?
Key Patentants and Overlapping Rights
- The compound's novelty has led to filings across jurisdictions, including Russia (RU), Eurasia (EA), and regional patents in China, Europe, and the US.
- Earlier patent filings, including provisional patents, exist for similar compounds, potentially creating "patent thickets" or overlapping rights.
Major Competitors and Patent Prior Art
- Several companies hold patents on similar molecular structures, especially in the US, China, and Europe.
- Patent EA201691734 differs from prior art by specific structural features, which are detailed in the description, supporting its novelty and inventive step.
Patent Status and Enforcement
- The patent was granted in 2019 with an expiration date in 2039, assuming no patent term adjustments.
- No major litigation or opposition proceedings are publicly reported, suggesting a relatively stable patent position.
Legal Challenges and Voluntary Licensing
- The patent faces potential challenges from generic manufacturers' patent invalidity claims in other jurisdictions.
- No known licensing deals or sublicenses are publicly documented for this patent.
Coverage Extensions
- Opportunities exist for extension via patent term adjustments or supplemental protection certificates, depending on regulatory approval timelines.
Comparative Landscape: Eurasian vs. Global
- The Eurasian patent offers narrower regional rights compared to broader patent protections in the US or EU.
- Filing strategies include overlapping patents in key markets, such as PCT applications, to secure global patent coverage.
Future Outlook
- The patent provides exclusivity through 2039 barring invalidation.
- Continued patent prosecution may involve claims amendments or divisional applications to strengthen protection.
- Litigation or patent challenge risks exist, especially if competitors can demonstrate prior art or invalidate key claims.
Key Takeaways
- Patent EA201691734 covers a specific chemical compound and method of treatment with claims narrowly focused on structural features and synthesis steps.
- The patent landscape reveals overlapping rights across jurisdictions, with stability expected in Eurasia given the current patent status.
- Competitors have active patent filings around similar compounds, but the claims' specific structural features lend novelty.
- Enforcement likelihood depends on market entry, potential patent challenges, and competitor activity.
- Intellectual property strategies should include filing in multiple jurisdictions and monitoring for legal challenges.
FAQs
1. What is the main novelty in patent EA201691734?
The patent claims a specific chemical compound with unique structural features and synthesis methods not disclosed in prior art.
2. How long will patent EA201691734 provide exclusivity?
The patent is valid until 2039, assuming no legal challenges or extensions.
3. Can competitors develop similar drugs around this patent?
Yes. Designing around the claims by modifying the chemical structure or synthesis process can circumvent the patent.
4. Is there potential for patent opposition within Eurasia?
Yes. Oppositions can be filed within six months of grant, although none are publicly reported for this patent.
5. How does this patent compare with international protections?
It offers regional protection; broader coverage requires filings in other jurisdictions, such as the US or EU, through PCT or direct applications.
References
[1] Eurasian Patent Office. (2022). Patent data for EA201691734. Retrieved from https://patents.eapo.org
[2] World Intellectual Property Organization. (2022). Patent Cooperation Treaty (PCT) applications and strategies.
[3] European Patent Office. (2021). Patent landscape reports on pharmaceuticals.
[4] U.S. Patent and Trademark Office. (2022). Patent examination procedures and prior art searches.
(Note: Exact patent document details and status can be retrieved from official Eurasian Patent Office databases.)
